As of Friday close, AbCellera Biologics Inc.’s (NASDAQ:ABCL) stock was down -$0.01, moving down -0.09 percent to $11.32. The average number of shares traded per day over the past five days has been 1,560,780 shares. 5 times new highs have been achieved over the past 5 days, with a $1.28 gain in that time frame. In the last twenty days, the average volume was 1,584,205, while in the previous 50 days, it was 2,709,626.
Since last month, ABCL stock retreated -1.48%. Shares of the company fell to $9.87 on 07/26/22, the lowest level in the past month. A 52-week high of $22.63 was reached on 01/03/22 after having rallying from a 52-week low of $5.42. Since the beginning of this year, ABCL’s stock price has dropped by -20.84% or -$2.98, and marked a new high 1 time. However, the stock has declined by -49.99% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
AbCellera Biologics Inc. (ABCL) last reported insider trading activity 53 days ago on Jun 14. Thermopylae Holdings Ltd., the 10% Owner of the company, purchased of 9,173 shares for $8.05 on Jun 14. It resulted in a $73,842 investment by the insider. Thermopylae Holdings Ltd. added 54,915 shares at an average price of $8.03 on Jun 13. The insider now owns 55,635,218 shares following the transaction. On Jun 06, 10% Owner Thermopylae Holdings Ltd. bought 64,545 shares at $7.50 apiece. The transaction was valued at $483,965.
Right now, AbCellera Biologics Inc. (ABCL) has a P/E ratio of about 17.31. Besides these, the trailing price-to-sales (P/S) ratio of 6.89, the price-to-book (PB) ratio of 2.66, and the price-to-cash flow ratio of 20.31 may also be considered.
In the year ended March 30, operating margins totaled 55.50%. Based on annual data, ABCL earned $170.79 million in gross profit and brought in $375.2 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 13.50%. Return on equity (ROE) for the past 12 months was 19.70%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ABCL’s revenue rose 35.96% to $139.31 million during the quarter, while net income inched up to $316.58 million. While analysts expected AbCellera Biologics Inc. to report $0.38 quarterly earnings, the actual figure was $0.54 per share, beating the consensus estimate by 42.10%. During the quarter, the company generated $229.92 million in EBITDA. The liabilities of AbCellera Biologics Inc. were 384.78 million at the end of its most recent quarter ended March 30, and its total debt was $40.28 million. The value of shareholders’ equity is $284.54 million.
This quick technical analysis looks at AbCellera Biologics Inc.’s (ABCL) price momentum. With a historical volatility rate of 47.10%, the RSI 9-day stood at 67.38% on 05 August.
With respect to its five-day moving average, the current AbCellera Biologics Inc. price is up by +12.75% percent or $1.28. At present, ABCL shares trade -2.25% below its 20-day simple moving average and +51.74% percent above its 100-day simple moving average. However, the stock is currently trading approximately +55.92% above its SMA50 and -29.12% below its SMA200.
Stochastic coefficient K was 87.02% and Stochastic coefficient D was 72.44%, while ATR was 0.58. Given the Stochastic reading of 81.19% for the 14-day period, the RSI (14) reading has been calculated as 63.30%. As of today, the MACD Oscillator reading stands at 0.58, while the 14-day reading stands at 0.67.
The Benchmark Company launched its rating on AbCellera Biologics Inc. (NASDAQ: ABCL) to a Buy in a note to investors on December 21, 2021. AbCellera Biologics Inc. (ABCL) has been rated Buy by analysts. According to 0 brokerage firms, ABCL is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate AbCellera Biologics Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $31.00, the current consensus forecast for the stock is $14.00 – $43.00. Based on these forecasts, analysts predict AbCellera Biologics Inc. (ABCL) will achieve an average price target of $30.13.